26. June 2026
Welcome to the Jantomarna Blog: Exploring the Future of RNA Therapeutics
Medical applications of mRNA biology are evolving at an extraordinary pace. In just a few years, the ability to express diverse proteins inside patients’ cells has transformed how researchers approach some of the most challenging diseases. From vaccines and cancer treatments to emerging therapies for rare diseases, mRNA has become one of the most exciting frontiers in modern biotechnology.
Yet alongside these scientific advances comes a new challenge: how do we design RNA sequences that not only perform their intended biological function, but can also be manufactured efficiently, safely, and at scale?
At Jantomarna, this question sits at the heart of everything we do. Our mission is to deliver mRNA sequences that function optimally for their intended applications, delivering efficacy, safety, and manufacturability without the need for lengthy and costly design-and-test cycles. Through our RNA design software and scientific expertise, we help organisations navigate the complex relationship between sequence design, biological performance and safety, and manufacturing requirements.
This blog has been created as a place to share knowledge, insights, and developments from across the RNA therapeutics landscape. We will explore the latest advances in mRNA design and therapeutic mRNA development. We will discuss emerging scientific discoveries, challenges in RNA manufacturing, and the technologies shaping the next generation of therapeutics. We will also share perspectives on the evolving role of computational approaches, RNA sequence optimisation tools, and the practical realities of translating promising research into effective treatments.
As the RNA sector continues to mature, the importance of robust and scientifically grounded design approaches will only increase. While advances in artificial intelligence and machine learning continue to generate significant interest, we believe that success in therapeutic development ultimately depends on a deep understanding of mRNA biology, sequence-function relationships, and the specific requirements of each application. Jantomarna Therapeutics was founded based on its founders’ decades-long track record in mRNA Biology, placing the company in a prime position to make unique contributions to the field.
Thank you for visiting our blog. If you are an RNA manufacturer looking to enhance your service offering through integrated mRNA design capabilities, or a biotechnology or pharmaceutical company developing RNA therapeutics and seeking support with therapeutic design challenges, we would be delighted to hear from you.
To discuss your requirements and explore how our technology and expertise can support your programmes, please contact us at info@jantomarna.co.uk.
About the author
Diala Nikolaeva is Customer Relations Manager at Jantomarna Therapeutics, where she supports the company's commercial engagement activities. Alongside her industry role, she conducts research in Business Analytics with a focus on healthcare, exploring how data-driven decision-making, strategic planning, and operational optimisation can improve healthcare delivery, identify opportunities for greater efficiency, reduce costs, and ultimately improve patient outcomes.
About the company
Jantomarna Therapeutics Limited is a private company limited by law registered in the UK with company number 16717863. Jantomarna’s mission is to harness the long-standing track records of its founders in mRNA Biology and Immunology for the design of mRNA Therapeutics with superior efficacy, patient safety, and manufacturability. We offer contract design of therapeutic sequences, co-development of therapeutics, and licensing of our design software. If you are interested in mRNA Therapeutics design contact us at info@jantomarna.co.uk .